Literature DB >> 22112426

Early survival and duration of hospital admission in rhabdomyolysis: ICNARC Case Mix Programme Database.

Colin A Hutchison, Krishna Patel, Tony Whitehouse.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 22112426      PMCID: PMC3388662          DOI: 10.1186/cc10492

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

New therapeutic measures are available for the management of rhabdomyolysis. To enable the design of future studies that will assess the clinical benefit of these interventions, we sought to first determine the current clinical outcomes of patients with rhabdomyolysis admitted to ICUs within England, Wales and Northern Ireland. We describe the duration of intensive care and hospital admissions associated with rhabdomyolysis, and the early survival measures for this population. Acute kidney injury secondary to high serum myoglobin levels is a frequent cause of morbidity and mortality for patients with rhabdomyolysis [1]. Theoretically the severity and duration of the tubulointerstitial lesion that results could be reduced if rapid removal of myoglobin from the circulation was undertaken to reduce the tubules' exposure to myoglobin [2]. Recent case reports have highlighted that dialysis membranes with high molecular weight cut-off points (50 kDa) are able to provide significantly higher clearance rates of myoglobin compared with standard high-flux dialysis membranes [3,4]. To determine the clinical benefit of providing rapid removal of myoglobin in patients with rhabdomyolysis, randomised controlled trials are now required to determine whether the procedure improves outcomes compared with standard care. Possible clinical outcomes for these studies would be the duration of hospital stay, rates of renal recovery and survival. To allow the design of these studies, current clinical outcomes for this population are required. We therefore interrogated a national database to determine the clinical outcomes for patients with rhabdomyolysis admitted to ICUs. The Case Mix Programme is the national clinical audit of adult, general critical care units in England, Wales and Northern Ireland coordinated by the Intensive Care National Audit & Research Centre. Data were extracted for 439,834 admissions to 210 ICUs from the Case Mix Programme Database, covering the period from January 2006 to December 2010. Admissions with rhabdomyolysis were identified from the reported primary (mandated), secondary (optional) and ultimate (optional) reasons for admission to the critical care unit and other conditions in past medical history, all coded using the Intensive Care National Audit & Research Centre Coding Method [5]. Survival data were extracted at discharge from the Case Mix Programme unit and hospital. Length of stay in the ICU was calculated in fractions of days from the dates and times of admission to and of discharge from the Case Mix Programme unit. Length of stay in hospital was calculated in days from the dates of original admission to and ultimate discharge from an acute hospital. Demographic and outcome data were available for 733 admissions to ICUs with rhabdomyolysis (Table 1). The ICU and hospital mortality rates for those admissions with rhabdomyolysis are high (21% and 31%, respectively). Additionally the median duration of hospital admission was substantial at 26 days (Table 1). Interventional studies are now required to determine whether providing a rapid removal of myoglobin to reduce the duration and severity of acute kidney injury in rhabdomyolysis will translate into improving these outcomes.
Table 1

Data for admissions with rhabdomyolysis to adult general ICUs in England, Wales and Northern Ireland

Number of admissions733
Age (years)
 Mean (standard deviation)54.5 (19.6) (n = 733)
 Median (IQR)56 (38, 71) (n = 733)
Gender, number of males (%)552 (75.3) (n = 733)
Critical care unit mortality, deaths (%)157 (21.4) (n = 733)
Acute hospital mortality,a deaths (%)221 (31.1) (n = 710)
Unit length of stay (days), median (IQR)
 Unit survivors4.6 (2.1, 8.9) (n = 576)
 Unit nonsurvivors2.0 (1.0, 7.4) (n = 157)
 All4.0 (1.8, 8.8) (n = 733)
Total acute hospital length of stay (days),a median (IQR)
 Unit survivors26 (14, 49) (n = 489)
 Unit nonsurvivors6 (2, 15) (n = 221)
 All20 (8, 40) (n = 710)

IQR, interquartile range. aExcluding readmissions to the critical care unit during the hospital stay.

Data for admissions with rhabdomyolysis to adult general ICUs in England, Wales and Northern Ireland IQR, interquartile range. aExcluding readmissions to the critical care unit during the hospital stay.

Competing interests

The authors declare that they have no competing interests.
  5 in total

1.  Development and testing of a hierarchical method to code the reason for admission to intensive care units: the ICNARC Coding Method. Intensive Care National Audit & Research Centre.

Authors:  J D Young; C Goldfrad; K Rowan
Journal:  Br J Anaesth       Date:  2001-10       Impact factor: 9.166

Review 2.  Rhabdomyolysis and acute kidney injury.

Authors:  Xavier Bosch; Esteban Poch; Josep M Grau
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

3.  Rhabdomyolysis and acute kidney injury.

Authors:  Nils Heyne; Martina Guthoff; Katja C Weisel
Journal:  N Engl J Med       Date:  2009-10-01       Impact factor: 91.245

4.  Rhabdomyolysis and acute kidney injury.

Authors:  Kolitha Basnayake; Paul Cockwell; Colin A Hutchison
Journal:  N Engl J Med       Date:  2009-10-01       Impact factor: 91.245

Review 5.  High cut-off dialysis membranes: current uses and future potential.

Authors:  Bertrand Gondouin; Colin A Hutchison
Journal:  Adv Chronic Kidney Dis       Date:  2011-05       Impact factor: 3.620

  5 in total
  1 in total

1.  Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis.

Authors:  Rebekah Fong Soe Khioe; Chris Skedgel; Andrew Hart; Michael Philip Nelson Lewis; Leo Alexandre
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.